Browsing Tag
UCB SA
2 posts
Could Biogen and UCB finally crack one of biotech’s toughest lupus markets?
Biogen and UCB have a lupus win, but one more Phase 3 test decides the story. See why dapirolizumab pegol matters now.
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
UCB is acquiring Neurona for up to $1.15 billion to deepen its epilepsy pipeline. Read what the deal means for growth, risk, and biotech competition.